ÂÜÀòÂÒÂ×

Emma McBurney serves as the Vice President and Head of Business Development and M&A at Biogen since October 2019, where Emma leads a team in negotiating and executing significant transactions across various therapeutic areas. Previously, Emma held the position of Executive Director of Business Development & Licensing at ReNetx and served as a Board Observer at Sanofi Genzyme, where responsibilities included overseeing business development strategies within the global rare diseases division. Emma's extensive experience in corporate business development at Boston Scientific involved managing M&A deal execution and financial analysis, complemented by an MBA from Yale and a B.S. in Business Management from Babson College. Notably, Emma has successfully executed over 60 transactions worth more than $12 billion during a recent collaboration at Biogen.